210 related articles for article (PubMed ID: 25912824)
1. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.
Huang J; Fairbrother W; Reed JC
Expert Rev Hematol; 2015 Jun; 8(3):283-97. PubMed ID: 25912824
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.
Kapoor I; Bodo J; Hill BT; Hsi ED; Almasan A
Cell Death Dis; 2020 Nov; 11(11):941. PubMed ID: 33139702
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.
Kedar R; Sabag O; Licthenstein M; Lorberboum-Galski H
Cancer; 2012 Dec; 118(24):6089-104. PubMed ID: 22692727
[TBL] [Abstract][Full Text] [Related]
4. [The role of chromosomal translocations in the pathogenesis of B-cell lymphomas].
Nishikori M
Rinsho Ketsueki; 2013 Oct; 54(10):1780-7. PubMed ID: 24064829
[No Abstract] [Full Text] [Related]
5. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.
Menendez P; Vargas A; Bueno C; Barrena S; Almeida J; De Santiago M; López A; Roa S; San Miguel JF; Orfao A
Leukemia; 2004 Mar; 18(3):491-8. PubMed ID: 14724650
[TBL] [Abstract][Full Text] [Related]
7. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.
Huynh T; Rodriguez-Rodriguez S; Danilov AV
Mol Cancer Ther; 2024 May; 23(5):619-626. PubMed ID: 38693903
[No Abstract] [Full Text] [Related]
8. Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18).
McCarthy BA; Boyle E; Wang XP; Guzowski D; Paul S; Catera R; Trott J; Yan XJ; Croce CM; Damle R; Yancopoulos S; Messmer BT; Lesser M; Allen SL; Rai KR; Chiorazzi N
Mol Med; 2008; 14(9-10):618-27. PubMed ID: 18633450
[TBL] [Abstract][Full Text] [Related]
9. Pathology, pathogenesis and molecular genetics of follicular NHL.
Leich E; Ott G; Rosenwald A
Best Pract Res Clin Haematol; 2011 Jun; 24(2):95-109. PubMed ID: 21658611
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 antisense therapy in B-cell malignancies.
Chanan-Khan A
Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
[TBL] [Abstract][Full Text] [Related]
11. Novel murine B-cell lymphoma/leukemia model to study BCL2-driven oncogenesis.
Meijerink JP; Van Lieshout EM; Beverloo HB; Van Drunen E; Mensink EJ; Macville M; Pieters R
Int J Cancer; 2005 May; 114(6):917-25. PubMed ID: 15645425
[TBL] [Abstract][Full Text] [Related]
12. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
Valentin R; Grabow S; Davids MS
Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
[TBL] [Abstract][Full Text] [Related]
13. Targeting BCL-2 regulated apoptosis in cancer.
Campbell KJ; Tait SWG
Open Biol; 2018 May; 8(5):. PubMed ID: 29769323
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCL-2 in B-cell lymphomas.
Davids MS
Blood; 2017 Aug; 130(9):1081-1088. PubMed ID: 28724540
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechingallate induces apoptosis in B lymphoma cells via caspase-dependent pathway and Bcl-2 family protein modulation.
Wang J; Xie Y; Feng Y; Zhang L; Huang X; Shen X; Luo X
Int J Oncol; 2015 Apr; 46(4):1507-15. PubMed ID: 25647297
[TBL] [Abstract][Full Text] [Related]
16. Lack of BCL-2 confers interferon-alpha sensitivity to B-cell lymphomas.
Karauzum SB; Yasar D; Dirice E; Imir N; Luleci G; Ozes ON
Growth Factors; 2007 Apr; 25(2):94-100. PubMed ID: 17852408
[TBL] [Abstract][Full Text] [Related]
17. New insights into redox homeostasis as a therapeutic target in B-cell malignancies.
Graczyk-Jarzynka A; Zagozdzon R; Muchowicz A; Siernicka M; Juszczynski P; Firczuk M
Curr Opin Hematol; 2017 Jul; 24(4):393-401. PubMed ID: 28402987
[TBL] [Abstract][Full Text] [Related]
18. Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.
Gobec M; Prijatelj M; Delić J; Markovič T; Mlinarič-Raščan I
Eur J Pharmacol; 2014 Nov; 742():81-8. PubMed ID: 25218986
[TBL] [Abstract][Full Text] [Related]
19. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update.
Siddiqui WA; Ahad A; Ahsan H
Arch Toxicol; 2015 Mar; 89(3):289-317. PubMed ID: 25618543
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
